- RNA pioneer and biotechnology innovator joins TransCode
Therapeutics Science Advisory Board to advance RNA
oncology
- Dr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which
developed and commercialized the first FDA-approved RNAi
drug
BOSTON, May 28, 2025
/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a
clinical-stage oncology company developing RNA-targeted
therapeutics for the treatment of cancer, today announced the
appointment of Phillip D. Zamore,
Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent
biotechnology innovator known for his pioneering work in RNA
interference (RNAi). Together with world-renowned scientists,
including Nobel Laureate, Dr Phillip
Sharp, he co-founded Alnylam Pharmaceuticals in 2002, which
developed the first FDA-approved RNAi drug.
Dr. Zamore currently serves as the Gretchen Stone Cook Professor
of Biomedical Sciences at the University of
Massachusetts Chan Medical School, where he chairs the RNA
Therapeutics Institute. Dr. Zamore's research has significantly
advanced the understanding of non-coding RNA and its role in health
and disease. He helped uncover how microRNAs are processed and
incorporated into RNA-induced gene-silencing complexes. His
contributions have been recognized by his election to the National
Academy of Sciences, the National Academy of Medicine, and the
American Academy of Arts and Sciences.
"We are honored to welcome Dr. Zamore to our Science Advisory
Board," said Dr. Zdravka Medarova, Chief Scientific Officer and
co-founder of TransCode Therapeutics. "His deep expertise in
RNA biology and his track record of translating scientific
discoveries into therapeutic innovations will be invaluable as we
advance our pipeline of RNA-targeted cancer therapies."
"TransCode's approach to targeting metastatic cancer through RNA
therapeutics is both innovative and promising," said Dr.
Zamore. "I look forward to contributing to the company's
mission of developing effective RNA-based treatments for patients
with cancer."
About TransCode Therapeutics
TransCode is a clinical-stage oncology company focused on
treating metastatic disease. The company is committed to defeating
cancer through the intelligent design and effective delivery of RNA
therapeutics based on its proprietary TTX nanoparticle platform.
The company's lead therapeutic candidate, TTX-MC138, is focused on
treating metastatic tumors which overexpress microRNA-10b, a
unique, well-documented biomarker of metastasis. In addition,
TransCode has a portfolio of other first-in-class RNA therapeutic
candidates designed to overcome the challenges of RNA delivery and
thus unlock therapeutic access to a variety of novel genetic
targets that could be relevant to treating a variety of
cancers.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, without limitation, statements about microRNAs and their
involvement in cancer, statements concerning the therapeutic
potential of TransCode's TTX-MC138 and other therapeutic
candidates, and statements concerning TransCode's TTX nanoparticle
platform. Any forward-looking statements in this press release are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: the risks
associated with drug discovery and development; the risk that the
results of clinical trials will not be consistent with TransCode's
preclinical studies or expectations or with results from previous
clinical trials; risks associated with the conduct of clinical
trials; risks associated with TransCode's financial condition and
its need to obtain additional funding to support its business
activities, including TransCode's ability to continue as a going
concern; risks associated with the timing and outcome of
TransCode's planned regulatory submissions; risks associated with
obtaining, maintaining and protecting intellectual property; risks
associated with TransCode's ability to enforce its patents against
infringers and defend its patent portfolio against challenges from
third parties; risks of competition from other companies developing
products for similar uses; risks associated with TransCode's
dependence on third parties; and risks associated with geopolitical
events and pandemics, including the COVID-19 coronavirus and
military actions. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause TransCode's actual results to differ from those contained in
or implied by the forward-looking statements, see the section
entitled "Risk Factors" in TransCode's Annual Report on Form 10-K
for the year ended December 31, 2024,
as well as discussions of potential risks, uncertainties and other
important factors in any subsequent TransCode filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of this release; TransCode undertakes no
duty to update this information unless required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transcode-therapeutics-appoints-dr-phillip-d-zamore-to-science-advisory-board-302466895.html
SOURCE TransCode Therapeutics, Inc.
